Compare · ARGX vs SLXN
ARGX vs SLXN
Side-by-side comparison of argenx SE (ARGX) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $50.47B, about 24782.9x SLXN ($2.0M).
- Over the past year, ARGX is up 41.5% and SLXN is down 96.6% - ARGX leads by 138.1 points.
- SLXN has been more active in the news (17 items in the past 4 weeks vs 6 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- argenx SE
- Silexion Therapeutics Corp
- Price
- $812.95+1.32%
- $4.85-0.82%
- Market cap
- $50.47B
- $2.0M
- 1M return
- +0.24%
- -24.34%
- 1Y return
- +41.53%
- -96.60%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 6
- 17
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest SLXN
- SEC Form PRE 14A filed by Silexion Therapeutics Corp
- Amendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Silexion Therapeutics Announces 1-for-10 Reverse Share Split
- Amendment: SEC Form 10-K/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Silexion Therapeutics Corp